Bull Harbor Capital LLC Buys Shares of 5,955 Edwards Lifesciences Corporation $EW

Bull Harbor Capital LLC bought a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 5,955 shares of the medical research company’s stock, valued at approximately $477,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Arkadios Wealth Advisors lifted its position in shares of Edwards Lifesciences by 7.3% during the first quarter. Arkadios Wealth Advisors now owns 4,621 shares of the medical research company’s stock worth $370,000 after purchasing an additional 315 shares during the last quarter. Amundi increased its stake in Edwards Lifesciences by 0.5% in the 1st quarter. Amundi now owns 2,670,209 shares of the medical research company’s stock worth $213,830,000 after buying an additional 12,171 shares during the period. Royal Bank of Canada lifted its holdings in Edwards Lifesciences by 18.1% during the 1st quarter. Royal Bank of Canada now owns 2,446,999 shares of the medical research company’s stock valued at $195,956,000 after buying an additional 375,801 shares in the last quarter. Empowered Funds LLC boosted its position in Edwards Lifesciences by 154.6% in the 1st quarter. Empowered Funds LLC now owns 82,019 shares of the medical research company’s stock valued at $6,568,000 after buying an additional 49,800 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in Edwards Lifesciences by 4.1% in the 1st quarter. The Manufacturers Life Insurance Company now owns 1,401,187 shares of the medical research company’s stock valued at $112,206,000 after buying an additional 54,579 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $83.98, for a total transaction of $85,575.62. Following the sale, the vice president owned 33,682 shares of the company’s stock, valued at approximately $2,828,614.36. This trade represents a 2.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 44,558 shares of company stock valued at $3,770,939 over the last 90 days. Corporate insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on EW. Mizuho upped their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. UBS Group began coverage on Edwards Lifesciences in a report on Tuesday. They issued a “buy” rating and a $110.00 price target for the company. BTIG Research increased their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Royal Bank Of Canada increased their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Barclays restated an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Trading Down 0.9%

NYSE EW opened at $86.17 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The company has a market capitalization of $49.62 billion, a price-to-earnings ratio of 49.52, a price-to-earnings-growth ratio of 2.18 and a beta of 0.86. The company’s 50-day simple moving average is $87.91 and its two-hundred day simple moving average is $83.89. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the previous year, the business posted $0.67 EPS. The company’s quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.